Journal: BMC Cancer

Article Title: The combination of poly(ADP-ribose) polymerase inhibitor and statin inhibits the proliferation of human castration-resistant and taxane-resistant prostate cancer cells in vitro and in vivo

doi: 10.1186/s12885-025-13895-6

Figure Lengend Snippet: Effect of simvastatin on DNA repair gene expression in prostate cancer and prostate stromal cells (PrSC). PC-3, 22Rv1, LNCaP-LA, LNCaP, and PrSC cells were incubated with the medium containing 10% FBS for 24 h, and the medium was switched to the indicated concentration of simvastatin in the medium containing 10% FBS. After 48 h, the total RNA ( A , C ) and total protein ( B , D ) were collected. ( A ) Comparison of mRNA expression levels of each gene in each cell without simvastatin. mRNA expression of BRCA1, BRCA2, RAD51, FANCD2, FANCG, FANCA, BARD1, RFC3, RFC4, and RFC5 was evaluated by performing real-time polymerase chain reaction tests, and the relative quantitative volume (RQV) was calculated by comparing the expression of β-actin. Values are expressed as mean ± standard deviation (SD) ( n = 3). * P < 0.05 vs. the other cells. ( B ) Comparison of protein levels of BRCA1 and RAD51 in each cell without simvastatin. The protein expression of BRCA1 and RAD51 was evaluated by western blotting. A representative experiment is shown, which was repeated three times with similar results. ( C ) Comparison of mRNA expression levels of each gene in each cell after treatment of simvastatin. mRNA expression of BRCA1, BRCA2, RAD51, FANCD2, FANCG, FANCA, BARD1, RFC3, RFC4, and RFC5 was evaluated by performing real-time polymerase chain reaction tests, and the relative quantitative volume (RQV) was calculated by comparing the expression of β-actin. Values are expressed as mean ± standard deviation (SD) ( n = 3). * P < 0.05 vs. 0 µM of each cell. ( D ) Comparison of BRCA1 protein levels in each cell after treatment of simvastatin. The protein expression of BRCA1 was evaluated by western blotting. A representative experiment is shown, which was repeated three times with similar results

Article Snippet: Human prostate cancer cell lines PC-3, LNCaP, and 22Rv1 were purchased from DS Pharma Biomedical (Osaka, Japan) and cultured in RPMI 1640 (Sigma-Aldrich, St. Louis, MO) supplemented with 10% fetal bovine serum (FBS) (Moregate, Bulimba, Australia).

Techniques: Gene Expression, Incubation, Concentration Assay, Comparison, Expressing, Real-time Polymerase Chain Reaction, Standard Deviation, Western Blot

Journal: BMC Cancer

Article Title: The combination of poly(ADP-ribose) polymerase inhibitor and statin inhibits the proliferation of human castration-resistant and taxane-resistant prostate cancer cells in vitro and in vivo

doi: 10.1186/s12885-025-13895-6

Figure Lengend Snippet: Effect of combination therapy with simvastatin and olaparib on androgen-independent prostate cancer cells. The cells were then incubated in a medium. After 48 h, the cells were cultured in a medium with or without simvastatin (PC-3, 2 µM; other cells, 5 µM) and olaparib (10 µM). After 72 h for PC-3, LNCaP, and PrSC and 120 h for LNCaP-LA and 22Rv1 cells, the number of viable cells was evaluated using MTS assay ( A ) and cell counts ( B ). Values are expressed as mean ± standard deviation (SD) (A; n = 5, B; n = 4). * p < 0.05. Sim; simvastatin, Ola; olaparib

Article Snippet: Human prostate cancer cell lines PC-3, LNCaP, and 22Rv1 were purchased from DS Pharma Biomedical (Osaka, Japan) and cultured in RPMI 1640 (Sigma-Aldrich, St. Louis, MO) supplemented with 10% fetal bovine serum (FBS) (Moregate, Bulimba, Australia).

Techniques: Incubation, Cell Culture, MTS Assay, Standard Deviation

Journal: BMC Cancer

Article Title: The combination of poly(ADP-ribose) polymerase inhibitor and statin inhibits the proliferation of human castration-resistant and taxane-resistant prostate cancer cells in vitro and in vivo

doi: 10.1186/s12885-025-13895-6

Figure Lengend Snippet: Effect of combination therapy with simvastatin and olaparib on tumor growth and BRCA1 expression in vivo in a 22Rv1 xenograft model. Graphic view of mean tumor volumes in 22Rv1 xenografts. Mice were injected with 22Rv1 cells (3 × 10 6 per site) and subsequently orally treated with simvastatin (100 mg/kg once daily) with or without olaparib (50 mg/kg once daily). Line graphs, mean ( n = 5); bars, standard deviation (SD); * p < 0.05 vs. the other group. BRCA1 mRNA expression in xenograft tissue was analyzed via quantitative real-time PCR (B). Values are expressed as mean ± SD ( n = 5). Sim; simvastatin, Ola; olaparib

Article Snippet: Human prostate cancer cell lines PC-3, LNCaP, and 22Rv1 were purchased from DS Pharma Biomedical (Osaka, Japan) and cultured in RPMI 1640 (Sigma-Aldrich, St. Louis, MO) supplemented with 10% fetal bovine serum (FBS) (Moregate, Bulimba, Australia).

Techniques: Expressing, In Vivo, Injection, Standard Deviation, Real-time Polymerase Chain Reaction

Journal: BMC Cancer

Article Title: The combination of poly(ADP-ribose) polymerase inhibitor and statin inhibits the proliferation of human castration-resistant and taxane-resistant prostate cancer cells in vitro and in vivo

doi: 10.1186/s12885-025-13895-6

Figure Lengend Snippet: Effect of combination therapy with simvastatin and olaparib on taxane-resistant prostate cancer cells. A and B . Comparison of DNA repair gene expression in 22Rv1 and 22Rv1-CR cells. A . mRNA expression of BRCA1, BRCA2, RAD51, BARD1, and FANCA was evaluated by RT-PCR, and the relative quantitative volume was calculated by comparing the expression of β-actin. Values are expressed as means ± standard deviations (SD) ( n = 3). * P < 0.05 vs. 22Rv1 cells. B . Protein expression of BRCA1, RAD51, BARD1, and FANCA was evaluated using western blotting. A representative experiment is shown, which was repeated three times with similar results. C and D . Cells were incubated in medium containing various concentrations of simvastatin. After 48 h, the total RNA ( C ) and total protein ( D ) were collected. A . mRNA expression of BRCA1, BRCA2, RAD51, BARD1, and FANCA was evaluated by RT-PCR, and the relative quantitative volume was calculated by comparing the expression of β-actin. Values are expressed as mean ± standard deviation (SD) ( n = 3). * P < 0.05 vs. 0 µM of each gene. D . Protein expression of BRCA1 and FANCA was evaluated by western blotting. A representative experiment is shown, which was repeated three times with similar results. E and F. Cells were incubated in the medium. After 48 h, the cells were cultured in a medium containing olaparib (10 µM) with or without simvastatin (5 µM). After 96 h, the number of viable cells was evaluated using the MTS assay ( E ) and cell counts ( F ). * P < 0.05. Sim; simvastatin, Ola; olaparib

Article Snippet: Human prostate cancer cell lines PC-3, LNCaP, and 22Rv1 were purchased from DS Pharma Biomedical (Osaka, Japan) and cultured in RPMI 1640 (Sigma-Aldrich, St. Louis, MO) supplemented with 10% fetal bovine serum (FBS) (Moregate, Bulimba, Australia).

Techniques: Comparison, Gene Expression, Expressing, Reverse Transcription Polymerase Chain Reaction, Western Blot, Incubation, Standard Deviation, Cell Culture, MTS Assay

Journal: BMC Cancer

Article Title: The combination of poly(ADP-ribose) polymerase inhibitor and statin inhibits the proliferation of human castration-resistant and taxane-resistant prostate cancer cells in vitro and in vivo

doi: 10.1186/s12885-025-13895-6

Figure Lengend Snippet: Effect of combination therapy with simvastatin and olaparib on γΗ2ΑΧ expression in androgen-independent or taxane-resistant prostate cancer cells. Cells were incubated in a medium. After 48 h, cells were cultured in a medium with or without simvastatin (PC-3; 2 µM, other cells; 5 µM) and olaparib (10 µM). Proteins were collected after 48 h for PC-3 and LNCaP-LA cells and 96 h for 22Rv1 and 22Rv1-CR cells. Protein expression of γΗ2ΑΧ was evaluated using western blotting. A representative experiment is shown, which was repeated three times with similar results

Article Snippet: Human prostate cancer cell lines PC-3, LNCaP, and 22Rv1 were purchased from DS Pharma Biomedical (Osaka, Japan) and cultured in RPMI 1640 (Sigma-Aldrich, St. Louis, MO) supplemented with 10% fetal bovine serum (FBS) (Moregate, Bulimba, Australia).

Techniques: Expressing, Incubation, Cell Culture, Western Blot

Journal: microPublication Biology

Article Title: SARS-Cov-2 small viral RNA suppresses gene expression via complementary binding to mRNA 3’ UTR

doi: 10.17912/micropub.biology.000790

Figure Lengend Snippet: ( A ) 12 svRNA sequences expressed in SARS-CoV-2 infected Calu-3 cells. Average start-end (position in the SC2 NC_045512 genome) alongside corresponding svRNA sequence (+ strand) are shown. Expression (in Reads Per Million) of individual svRNA sequences are indicated under the corresponding SRR Identifiers (Wyler et al. 2021). ( B ) mFold predicted secondary structure of svRNA-29094 hairpin (Zuker 2003). The excised svRNA is highlighted in green and included below the hairpin. ( C ) Alignment of putative target mRNA 3’UTRs with the svRNA-29094 sequence. ( D ) PC3 cell lysates were collected at 24- and 48-hours after co-transfection of a small RNA mimic and a psiCHECK-2 reporter expressing Renilla luciferase mRNA harboring the SLC5A9 target site (shown in C) in its 3’UTR. Graph depicts Relative Light Units (RLU) of Renilla luciferase normalized to firefly luciferase (internal control independently expressed from psiCHECK-2). 29094 mimic, commercially synthesized small RNA identical to the svRNA 29094 sequence depicted in B. Ctl mimic, standard Dharmacon negative control microRNA mimic. Error bars indicate standard deviation (n=3). P-values were obtained using a standard t-test.

Article Snippet: The prostate cancer PC3 cell line was obtained from GenLantis (San Diego, CA) and cultured in a humidified atmosphere with 5% CO2 at 37°C in MEM (Mediatech, Herndon, VA) supplemented with 10% fetal bovine serum (Hyclone, Logan, UT), 25 mg/ml streptomycin and 25 I.U. penicillin (Mediatech).

Techniques: Infection, Sequencing, Expressing, Cotransfection, Luciferase, Control, Synthesized, Negative Control, Standard Deviation